The US Congressional Budget Office (CBO) has determined that H.R. 2430, the "pre-conferenced" version of the FDA Reauthorization Act of 2017 (FDARA) would shave $72 million off the deficit over the next 10 years in terms of revenue and direct spending, largely attributable to two provisions not included in the original Senate version.
FDARA Would Trim $72 Million From Deficit Over 10 Years, CBO Says
CBO score of the FDA use fee reauthorization bill only looks at changes in revenues and direct spending on a few provisions, and does not factor in changes in discretionary spending.
